Description
Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle.{3178,1752} Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor, and does not bind appreciably to any of the other murine EP receptors or DP, TP, FP, or IP receptors.{6640} The EC50 for the stimulation of cAMP by butaprost in COS cells transfected with the human EP2 receptor is about 5 µM, while the EC50 for PGE2 in this assay is about 43 nM.{3178} Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells.{3317}
Formal name: 9-oxo-11α,16S-dihydroxy-17-cyclobutyl-prost-13E-en-1-oic acid, methyl ester
Synonyms: 15-deoxy-16S-hydroxy-17-cyclobutyl PGE1 methyl ester|TR 4979
Molecular weight: 408.6
CAS: 69685-22-9
Purity: ≥98%
Formulation: A solution in methyl acetate
Product Type|Biochemicals|Lipids|Prostaglandins||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway